Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNA recognition motif domain containing protein | 0.0325 | 0.9532 | 0.9532 |
Echinococcus granulosus | geminin | 0.0175 | 0.433 | 0.433 |
Schistosoma mansoni | tar DNA-binding protein | 0.0325 | 0.9532 | 0.9532 |
Brugia malayi | RNA binding protein | 0.0325 | 0.9532 | 0.9532 |
Schistosoma mansoni | tar DNA-binding protein | 0.0325 | 0.9532 | 0.9532 |
Schistosoma mansoni | hypothetical protein | 0.0175 | 0.433 | 0.433 |
Echinococcus multilocularis | tar DNA binding protein | 0.0325 | 0.9532 | 0.9532 |
Echinococcus granulosus | high affinity choline transporter 1 | 0.0339 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0325 | 0.9532 | 0.9532 |
Schistosoma mansoni | tar DNA-binding protein | 0.0325 | 0.9532 | 0.9532 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0236 | 0.6439 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0325 | 0.9532 | 0.9532 |
Schistosoma mansoni | tar DNA-binding protein | 0.0325 | 0.9532 | 0.9532 |
Schistosoma mansoni | hypothetical protein | 0.0175 | 0.433 | 0.433 |
Echinococcus granulosus | tumor protein p63 | 0.0335 | 0.9867 | 0.9867 |
Echinococcus multilocularis | geminin | 0.0175 | 0.433 | 0.433 |
Loa Loa (eye worm) | hypothetical protein | 0.0339 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0325 | 0.9532 | 0.9532 |
Echinococcus multilocularis | high affinity choline transporter 1 | 0.0339 | 1 | 1 |
Schistosoma mansoni | high-affinity choline transporter | 0.0339 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0325 | 0.9532 | 0.9532 |
Loa Loa (eye worm) | TAR-binding protein | 0.0325 | 0.9532 | 0.9532 |
Echinococcus multilocularis | tumor protein p63 | 0.0335 | 0.9867 | 0.9867 |
Brugia malayi | TAR-binding protein | 0.0325 | 0.9532 | 0.9532 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 10 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 10 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | > 1.25 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | > 1.25 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 1.814 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 1.814 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0.01449 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.